Obesity Medicine

Latest News

Enobosarm Preserves Muscle Mass During Weight Loss with Semaglutide, Advances to Phase 3 Program, Veru Reports / image credit ©Design36/Shutterstock.com
Enobosarm Significantly Preserves Muscle Mass When Added to Semaglutide, Advances to Phase 3 Development Program

May 29th 2025

Enobosarm added to semaglutide shows promising results in preserving muscle mass while promoting fat loss in older adults, according to developer Veru, Inc.

ASCO 2025: GLP-1 Receptor Agonists Linked to Modest Reduction in Obesity-Related Cancer Risk
ASCO 2025: GLP-1 Receptor Agonists Linked to Modest Reduction in Obesity-Related Cancer Risk

May 28th 2025

A Half Dose of Semaglutide Yields Weight Loss Equivalent to a Whole Dose in Combination with Online Clinic Program / image credit University of Cophenhagen
A Half Dose of Semaglutide Yields Weight Loss Equivalent to Clinical Trial Doses in Combination with Online Support Program

May 13th 2025

Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study
Tirzepatide Demonstrates Greater Weight Loss Than Semaglutide in Head-to-Head Study

May 12th 2025

Genetic Risk Score Identifies Individuals Likely to Report Adverse Events from GLP-1 Mimetic Therapy / image credit Andres Acosta Phenomix Sciences
Genetic Risk Score Identifies Individuals Likely to Report Adverse Events from GLP-1 Mimetic Therapy

May 12th 2025

<1
...
5152535455
© 2025 MJH Life Sciences

All rights reserved.